Carcinosarcoma

14 registered clinical trials studyying Carcinosarcoma — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Agnostic Therapy in Rare Solid Tumors NCT06638931	Instituto do Cancer do Estado de São Paulo	Phase 2
Recruiting	ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer NCT05542407	UNC Lineberger Comprehensive Cancer Center	Phase 1
Terminated	(VELA) Study of BLU-222 in Advanced Solid Tumors NCT05252416	Blueprint Medicines Corporation	Phase 1
Unknown	Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma NCT05265793	Fudan University	Phase 2
Completed	Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus. NCT04458597	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	N/A
Completed	ZW25 in Women With Endometrial Cancers NCT04513665	Memorial Sloan Kettering Cancer Center	Phase 2
Withdrawn	Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1 NCT03933761	Australia New Zealand Gynaecological Oncology Group	Phase 2
Terminated	Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage NCT04688749	Aristotle University Of Thessaloniki	—
Recruiting	GISAR German Interdisciplinary Sarcoma Registry NCT04122872	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	—
Unknown	Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Pacli NCT03570437	University of Manchester	Phase 2
Completed	A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial End NCT03395080	Leap Therapeutics, Inc.	Phase 2
Completed	A Study of Nivolumab in Selected Uterine Cancer Patients NCT03241745	Memorial Sloan Kettering Cancer Center	Phase 2
Completed	Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarc NCT00815945	AGO Study Group	Phase 2
No Longer Available	Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors NCT04681248	Leap Therapeutics, Inc.	—